Pinned Tweet
Biotech is not crowded. Two targets are.
19 biotechs are chasing CD19:
$LYEL $ADCT $IBRX $CLYM $ALLO $AUTL $CABA $KYTX $FATE $DTIL $TGTX $CRSP $LEGN $XNCR $CGEM $SANA $ARTV $IPSC $NKTX
Median value: $0.60B.
Only 2 of the 19 have reached Phase 3.
We mapped the whole small/mid-cap biotech market. Here is what it looks like ↓
1
5
1,972
AbbVie $ABBV bought Apogee in Q3. That one deal took out $1.13B of VR Adviser's stakes, 34% of its book at the end of Q2.
No other of the 43 specialist funds lost as big a share of its book to a takeover.
1
242
13F = disclosed US long positions at quarter end, not fund performance.
VR Adviser's full Q3 2026 holdings: biopharmawatch.com/individua…
Full 13F report: biopharmawatch.com/blog/biot…
41
In the quarter Celcuity $CELC won FDA approval, the other 42 specialist funds net sold $469M of it, led by Baker Bros (-$324M) and Avoro (-$199M).
Tang went the other way: +$16M, to a $116M stake.
1
267
13F = disclosed US long positions at quarter end, not fund performance.
Tang's full Q3 2026 holdings: biopharmawatch.com/individua…
Full 13F report: biopharmawatch.com/blog/biot…
57
📊 The Biotech Tape | Tue Nov 17
A Phase 3 win and a sell-off: SELLAS rose 156%, Cue Biopharma fell 80%.
📈 Up
$SLS +156% · Phase 3 REGAL win: 41% lower risk of death in AML
$AYTU +46% · To be acquired by Rosemont for $2.70 a share in cash
$GLSI +36% · Two abstracts accepted for posters at SABCS 2026
$CING +26% · No new release; rebound after Monday's 13% drop
$GANX +26% · Phase 1b rexaceract: Parkinson's motor scores stable at 12 months
$MAIA +24% · Phase 2 THIO-101: 88% disease control in 3rd-line NSCLC
$INO +16% · No company release
$NRXP +14% · Q3 report: launch of its FDA-approved ketamine underway
$KROS +13% · New $5M buyback after a $20M milestone payment
$RZLT +12% · No new release; rebound after last week's $100M offering
📉 Down
$CUE −80% · Sold off after its Q3 update with more Phase 2 CSU data
$ENTA −19% · EDP-978 Phase 1 data pushed to 1Q 2027
$RLMD −17% · No new release; second day down after Monday's 14% drop
$OMER −17% · Q3 net loss $57.4M incl. $62.0M non-cash derivative loss
$LXEO −12% · Gave back Monday's 13% gain on interim LX2020 data
$CRBP −11% · Day after its CRB-913 Phase 1b obesity data
$FATE −11% · No new release; second straight 11% drop
$EPRX −10% · No new release; second straight 10% drop
$IDYA −10% · FDA aligned on registrational trials for IDE849
$SMMT −10% · Second day down after the FDA rejected ivonescimab
📅 Tomorrow's FDA decisions and data readouts are on the calendar, link below 👇
1
287
📅 Every upcoming FDA decision and data readout, with our approval odds: biopharmawatch.com/fda-calen…
37
13F = disclosed US long positions at quarter end, not fund performance.
Casdin's full Q3 2026 holdings: biopharmawatch.com/individua…
Full 13F report: biopharmawatch.com/blog/biot…
41





